Alza Corporation

Powderject Research Limited

Adamas Pharmaceuticals, Inc.

Other

Boston Scientific Scimed, Inc.

Syva Company

Terry L Burkoth

Patrick S Wong

Liang C Dong

Brian L Barclay

Jerry D Childers

Michael H Dealey

Robert M Gale

Eun Soo Lee

James B Eckenhoff

Lina T Taskovich

John P Carr

Atul D Ayer

Jeremy C Wright

Timothy J Fultz

Gregory T Went

Anthony L Kuczynski

Steven J Prestrelski

Joseph C Deters

Yuh-Fun Maa

Tyler Watanabe

David Chernoff

Jack Nguyen

Mickey S Urdea

Paul Spence

Rowan Chapman

Andrew Gordon Muddle

Edwin F Ullman

Jerome Segal

David Francis Sarphie

Richard D Hamlin

Barbara Horsey O'Connor

Neal Scott

Nieves M Crisologo

Sung Yun Kwon

Russell D Beste

Lih-Bin Shih

Su Ll Yum

Martin E Packard

Roderick Hafner

Linda Maree Porter

Kits comprising an M2 inhibitor selected from amantadine and rimantadine; ribavirin, and a neuraminidase inhibitor (NAi) in an amount that is antivirally effective in the combination, an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin and a neuraminidase inhibitor are provided for the treatment of influenza. Some embodiments of the kits comprise an oral dosage form containing 75-250 mg of the M2 inhibitor, an oral dosage form comprising 100-400 mg of ribavirin, and a neuraminidase inhibitor.

Compositions and kits for treating influenza

Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.

The present invention relates to a catheter with an expandable distal end for delivering one or more medicaments. The catheter is manufactured with materials of construction that allow the transfer of electrical energy from the proximal end of the catheter to the distal expandable end. The catheter also has a means for controlling or manipulating the expandable distal end to expand and contract into various configurations. The distal end of the catheter is processed by a specific method of manufacturing whereby the expandable distal end is coated with one or more layers of a hydrogel copolymer wherein at least one layer of which coating encapsulates one or more medicaments and zero or more charged carriers to facilitate the electrophoretic and electro-osmostic mobilities of the medicaments.

Polymer coated device for electrically medicated drug delivery

A process for producing a powder comprises spray freeze-drying an aqueous solution or suspension comprising a pharmaceutical agent, said solution or suspension having a solids content of 20% by weight or more. The spray freeze-dried powder may be administered to a subject via a needleless syringe.

Spray freeze-dried compositions

New compositions formed from the combination of an active substance with a hydrogel carrier moiety are provided. The compositions are suitable for use in high-velocity transdermal particle injection techniques. Methods of providing the new compositions are also provided. In addition, methods for administering pharmacologically active agent to a subject are provided. These methods are useful for delivering drugs, biopharmaceuticals, vaccines and diagnostics agents.

Hydrogel particle formulation

A method is provided for in vivo or ex vivo delivery of a preparation of powdered nucleic acid molecules into vertebrate tissue for transformation of cells in the tissue using needleless injection techniques. The method can be used to deliver therapeutically relevant nucleotide sequences to cells in mammalian tissue to provide gene therapy, elicit immunity or to provide antisense or ribozyme functions. A method for providing densified processed pharmaceutical compositions is also described. The method is used to convert non-dense pharmaceutical powders or particulate formulations into densified particles optimally suited for transdermal delivery using a needleless syringe. The method is also used to optimize the density and particle size of powders and particulate formulations for subsequent transdermal delivery thereof. Densified pharmaceutical compositions formed by the present methods are also provided.

Particle delivery techniques

An apparatus for sensing an analyte is described, wherein the apparatus includes an interface contact element that is used to establish an interface with a quantity of body fluid. The interface contact element is adapted to facilitate diffusion of a target analyte across the interface essentially free of net mass fluid transport. The quantity of body fluid is exposed to the interface contact element through micro-pathways. The apparatus can also include a sensing material adapted to sense the target analyte with at least one analytical method. Methods for using the apparatus in a non- or minimally invasive monitoring technique are also described.

Non- or minimally invasive monitoring methods

A composition of matter for application to a body surface or membrane to administer oxybutynin by permeation through the body surface or membrane, the composition comprising, in combination, the oxybutynin to be administered, in a therapeutically effective amount; and a permeation-enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactic ester or a mixture of lactate esters; present in specific concentrations.

Monoglyceride/lactate ester permeation enhancer for oxybutnin

A dosage form is disclosed comprising means for lessening the tackiness and/or irritation of the components of the dosage form to mucosal tissue. The dosage form provides means for forming in the dosage form a floc comprising a drug, which floc, when delivered from the dosage form, lessens the tackiness and/or irritation of the mucosal tissue of a warm-blooded recipient.

Method for administering steroid

Compositions, devices, and methods for transdermal administration of an active agent are disclosed using a novel dual permeation enhancer mixture comprising lauryl acetate and a monoglyceride, preferably glycerol monolaurate. The dual permeation enhancer mixture comprising lauryl acetate is a potent permeation enhancer and provides stable systems which are more readily characterized.

Skin permeation enhancer compositions comprising glycerol monolaurate

Dosage form comprising hydrophilic polymer

Monoglyceride/lactate ester permeation enhancer for oxybutynin

A device for the transdermal administration of oxybutynin comprising a microporous tie layer located between the oxybutynin reservoir and the contact adhesive. The tie layer eliminates blooming and delamination and has no appreciable adverse effect on either the oxybutynin flux or release rate from the device.

Oxybutynin transdermal device having decreased delamination

The present invention is directed to an improvement in a delivery device, the device comprising a wall that surrounds an internal lumen or compartment which contains a beneficial agent or medicament formulation, an expandable driving member and an optional density member, and having an exit means, and wherein the improvement comprises prehydrating the delivery device as a means for advancing the beginning or startup of agent delivery from the delivery system to give earlier release of beneficial agent to the environment of use. An embodiment of the invention concerns a fluid reservoir in contact with the expandable driving member to provide prehydration of the device.

Long-term delivery device with early startup

Growing community of inventors

Palo Alto, CA, United States of America

Terry L Burkoth